当前位置: 首页 > 期刊 > 《高血压杂志》 > 1999年第4期
编号:10255602
老年人高血压呈现Ouabain抵抗现象及非洛地平干预的影响
http://www.100md.com 2003年8月25日 《高血压杂志》 1999年第4期
     作者:谭建聪 祝之明 刘光耀 刘晓莉 徐有奇

    单位:谭建聪 祝之明 刘光耀:第三军医大学大坪医院野战外科研究所心内科高血压中心;肾内科:刘晓莉;徐有奇:核医学科,重庆 400042

    关键词:高血压;肾素-血管紧张素系统;哇巴因;钙拮抗剂

    高血压杂志990408

    摘要 目的:探讨老年人高血压Ouabain抵抗现象机理及钙拮抗剂非洛地平对其影响。

    方法:42例高血压(EH)病人,分为老年EH组和非老年EH组。采用放射免疫分析法测定血浆肾素活性(PRA)、血管紧张素Ⅱ(AngⅡ)、血浆内源性类地高辛物质(EDLS)浓度、EDLS与红细胞结合率(RBC-D%);测定加哇巴因(ouabain)后红细胞内[Na+]i变化,计算出ouabain敏感Na+外流速度常数( oKos,反映总的Na+泵活性);[Na+]i用火焰光度法测定。EH组服非洛地平治疗3周后复查。
, 百拇医药
    结果:老年EH组RBC-D%、PRA、AngⅡ明显低于非老年EH组,血浆EDLS 和oKos高于非老年EH组,Na+泵活性呈现Ouabain抵抗现象。在老年EH组中,AngⅡ与年龄和RBC-D%呈负相关,PRA与EDLS呈负相关。降压治疗后,老年EH病人PRA、AngⅡ、Na+泵活性升高,非老年EH者仅Na+泵活性升高,EDLS、PRA、AngⅡ无显著变化。

    结论:老年EH病人EDLS与细胞膜亲合力下降,呈现Ouabain抵抗现象,通过影响钠代谢抑制PRA、AngⅡ分泌。钙拮抗剂非洛地平降压治疗可部分改善这种异常。

    要点:老年高血压病人组EDLS浓度,总的Na+泵活性 oKos高于非老年高血压组,而EDLS与红细胞结合率(RBC-D%),PRA和AngⅡ水平明显低于非老年高血压组。表明在老年高血压病人中,一定量EDLS抑制细胞膜钠泵的生物学效应下降,钠泵呈现Ouabain抵抗现象。经非洛地平治疗后老年高血压组PRA、AngⅡ水平升高,EDLS稍降低,总的Na+泵活性 oKos升高,但尚未达正常水平。非老年组高血压病人在较老年组高血压组病人较低血浆EDLS浓度下,细胞钠泵活性已明显受抑制,不表现抵抗或抵抗程度较轻。
, 百拇医药
    中图分类号:R544.1;Q591;R972 文献标识码:A

    文章编号:1006-2866(1999)04-0305-03

    The Ouabain-Resistant Phenomenon and the Effects of Felodipine on it in Elderly Patients with Essential Hypertension

    TAN Jiancong1,ZHU Zhiming1,LIU Guangyao1,LIU Xiaoli2,XU Youqi3

    (1.Department of Cardiology and Hypertension Center,2.Renal Department 3.Department of Nuclear Medicine,Daping Hospital ,Third Military Medical University,Chongqing,400042,China)
, 百拇医药
    ABSTRACT Objective:To investigate the mechanism of the ouabain-resistant phenomenon and the effects of felodipine on it in elderly patients with essential hypertension(EH).

    Methods:42 essential hypertensives were divided into two groups,22 aged patients(AP) and 20 non-aged patients(NAP),25 aged healthy subjects as normotensive controls(NT).The rate of125I-digoxin binding to red blood cells (RBC-D%),plasma endogenous digoxin-like substances(EDLS),plasma renin activity(PRA),angiotensinⅡ(AngⅡ) were measured with radioimmunoassay.The rate constant of ouabain-sensitive sodium efflux (oKos.h-1) was measured as 50% increases in erythrocyte Na+ concentration during incubation with ouabain 2 h,oKos was calculated by equation.intracellular Na+ concentration with flame photometry.After treated by felodipine for 3 weeks,all the measurements were reexamined in hypertensive patients.
, 百拇医药
    Results:AP group demonstrated a significant higher plasma EDLS and oKos ,but RBC-D%,PRA and AngⅡ were lower compared with those in NAP group.In AP group,AngⅡ was negatively correlated with age and RBC-D% (r=-0.45; r=-0.47,respectively,all P<0.05),PRA was negatively correlated with EDLS(r=-0.44,P<0.05).After treatment with felodipine,PRA、AngⅡ、oKos increased in AP group;only oKos increased in NAP group.
, 百拇医药
    Conclusion:Our data show that the ouabain-resistant phenomenon exists in aged patients with hypertension.The ouabain-resistance inhibits RAS via sodium metabolism.Felodipine may partially correct the abnormal state in hypertensive patients.

    Key Words:hypertension; ouabain; renin-angiotensin system; Calcium antagonist

    许多研究显示[1],老年人EH大多为低肾素型,肾素-血管紧张素系统(renin angiotensin system,RAS)活性随年龄增长而降低。血浆肾素活性(plasma renin activity,PRA)、血管紧张素Ⅱ(angiotensinⅡ,AngⅡ)是调节人体血压、水、电解质平衡的重要物质,为何在老年人EH病人中被抑制,机理不明了。近年发现EH病人血浆内源性类地高辛物质(endogenous digoxin-like substances,EDLS)浓度增高[2,3],EDLS同样具有调节人体血压、水、电解质平衡的作用,尚不清楚它与RAS怎样相互作用影响血压。为此,我们观察了老年、非老年EH病人服非洛地平治疗前后血浆EDLS浓度、EDLS与红细胞结合率(RBC-D%)、红细胞ouabain敏感Na+外流速度常数(the rate content of ouabain-sensivitive sodium efflux,oKos)、PRA、 AngⅡ等,初步探讨了老年人高血压Ouabain抵抗现象机理及钙拮抗剂非洛地平疗效。
, 百拇医药
    MATERIALS AND METHODS

    1 对象:42例EH病人中,老年EH病人22例 (年龄60~80岁,平均年龄67±6岁,其中男12例,女10例);非老年EH病人20例(年龄43~59岁,平均年龄52±5岁,其中男11例,女9例)。EH判断标准:收缩压≥140 mmHg及/或舒张压≥90 mmHg。全部病例均经详细询问病史、查体、实验室检查,剔除继发性高血压,检查前停服所有药物1周。取血标本后,予非洛地平口服治疗(5~10 mg,1/d)3周后复查。选择25名健康老年人作对照组(年龄60~74岁,平均年龄65±5岁,其中男13名,女12名)。

    2 方法:早晨空腹抽取静脉血,用肝素抗凝,将标本置于4℃、2500 g离心10分钟,分别取血浆和红细胞作下述测定:

    2.1 血浆EDLS、PRA、AngⅡ浓度采用放射免疫分析法(由上海放射免疫分析技术研究所*****放射免疫分析试剂盒)。
, 百拇医药
    2.2 EDLS与红细胞结合率(红细胞-125I-地高辛结合率,RBC-D%)测定:采用放射免疫分析法,按本院建立的方法测定[4]。取0.1 ml洗涤过的红细胞加125I-地高辛0.1 ml,生理盐水0.1 ml混匀,4℃过夜,离心去上清,用γ计数器测定红细胞cpm,按下式计算出:,式中A为0.1 ml125I-地高辛cpm,B为红细胞-125I-地高辛cpm,C为本底cpm。

    2.3 红细胞哇巴因敏感钠外流速度常数(oKos.h-1)测定[5], 取全血加哇巴因(0.1 mmol/L)37℃水浴2小时,[Na+]i升高的一半为哇巴因敏感钠外流(ouabain sensitive sodium efflux,oMos,mmol.h-1.kg-1)。[Na+]i用HG-3型火焰光度计上测定。oKos按下式计算:oKos=,式中[Na+]w为洗涤过的红细胞。[Na+]i哇巴因敏感钠外流是Na+泵活动所致,因此,oKos反映总的Na+泵活性。
, 百拇医药
    3 统计分析:所有数据用未配对资料t检验和相关分析处理。结果用均值±标准差(±s)表示。

    RESULTS

    1 研究对象的临床特点:老年EH病人收缩压(SBP)高于非老年EH病人,但舒张压(DBP)低于非老年EH病人,体重指数(BMI)两组无明显差别(表1)。

    Tab 1 Clinical characteristics of the study population

    n

    Sex(M/F)

    Age

    SBP(mmHg)
, 百拇医药
    DBP(mmHg)

    MAP(mmHg)

    BMI(kg/m2)

    NT

    25

    14/11

    65±5

    125±7

    77±6

    93±8

    23.7±2.1

    Aged EH patient
, http://www.100md.com
    22

    12/10

    67±6#

    188±27**#

    95±8**#

    143±12**#

    25.5±2.3

    non-aged EH

    20

    11/9

    52±5
, 百拇医药
    176±23**

    104±7**

    125±10**

    23.3±3.4

    *:P<0.05,**P<0.01 vs NT;#P<0.05 vs NAP BMI body mass index;NT:aged healthy subjects as normotensive controls

    2 降压治疗前各参数结果:老年EH病人血浆EDLS浓度、oKos高于非老年EH病人,RBC-D%、PRA、AngⅡ低于非老年EH病人,两组EH病人血浆EDLS浓度均高于正常对照组, oKos、 RBC-D%、 PRA、AngⅡ均低于正常对照组,[Na+]i三组间无显著差别(表2,)。
, 百拇医药
    Tab 2 The results of parameters of NT,APEH and NAPEH group before and after treatment

    Group NT

    Aged EH patient

    non-aged EH

    Before

    After treat

    Before

    After treat

    SBP

    125±7
, 百拇医药
    188±27**#

    165±21++

    176±23**

    152±15++

    DBP

    77±6

    95±8**#

    84±15+

    104±7**

    88±14++
, http://www.100md.com
    MAP

    93±8

    143±12**#

    121±17++

    125±10**

    106±9++

    PRA(ng*ml-1*h-1)

    1.53±1.03

    0.48±0.21*#

    1.2±0.6++
, 百拇医药
    0.73±0.60*

    0.68±0.29

    AngⅡ(pg/ml)

    76±23

    35±17*##

    55±28+

    68±32

    59±30

    EDLS(ng/L)

    271±56

    459±86*#
, 百拇医药
    432±113

    402±81*

    431±140

    RBC-D(%)

    20.2±7.9

    10.3±1.7*#

    6.9±2.3+

    12.7±2.9*

    6.7±3.5+

    oKos(k/h)
, http://www.100md.com
    0.25±0.05

    0.18±0.02*#

    0.21±0.06+

    0.16±0.02*

    0.19±0.05+

    [Na+]i(mmol/L)

    9.0±1.2

    10.1±1.0

    11.3±3.4

    10.5±1.7
, 百拇医药
    11.0±1.4

    *:P<0.01 vs NT; #P<0.05,##:P<0.01 vs NAP; +:P<0.05,++P:<0.01 vs before treatment.

    EDLS:plasma endogenous digoxin-like substances ; AngⅡ:angiotensinⅡ; PRA:plasma renin activity ; RBC-D%:The rate of 125I-digoxin binding to red blood cells; oKos(k.h-1):The rate constant of ouabain-sensitive sodium efflux

    3 降压治疗后各参数结果
, 百拇医药
    3.1 老年EH组PRA、AngⅡ、oKos升高,EDLS略降低但未达显著水平。

    3.2 非老年EH组PRA、AngⅡ无明显变化,oKos升高,EDLS无显著变化(表2)。

    4 治疗前各参数相关性检验:老年EH组AngⅡ分别与年龄和RBC-D%呈负相关(分别r=-0.45; r=-47,均P<0.05 ),RBC-D%分别与EDLS、oKos呈负相关(分别r=-0.51; r=-0.46,均P<0.05),PRA与EDLS呈负相关(r=-0.44,P<0.05)。

    Fig 1 EDLS in different groups before and after treatment
, http://www.100md.com
    Fig 2 RBC-D(%) in different groups before and after treatment

    DISCUSSION

    老年人EH临床上大都表现为较高的SBP和相对较低的DBP,脉压差随年龄增大,而PRA、AngⅡ逐年降低。这显然与老年前期及青中年EH表现不同,提示老年人EH发生机理不同或EH演变过程中影响血压的因素也在演变。本实验显示,老年EH病人血浆EDLS(Ouabain类物质,钠泵抑制物)和钠泵活性较非老年EH病人高,而反映EDLS与膜亲和力的指标RBC-D%较低。EDLS仅作用钠泵上洋地黄结合位点,而不作用于其它离子泵[6]。所以,RBC-D%降低可看成是EDLS与膜钠泵亲和力降低。当RBC-D%降低时,为达到一定的EDLS与膜结合量,机体必须分泌更多EDLS。因此,血浆EDLS增加可能是一种代偿反应。老年EH病人RBC-D%较非老年EH病人低,故EDLS分泌更多。EDLS为细胞膜Na+泵活性抑制物。老年EH病人在较高的血浆EDLS浓度下,细胞膜钠泵活性虽受一定抑制,但高于非老年EH病人,钠泵活性相对较高,表明在老年EH病人中,一定量EDLS抑制细胞膜钠泵的生物学效应下降,钠泵呈现Ouabain抵抗现象。其原因可能是在老年人EH中,升高的EDLS不足以抵消RBC-D%降低因素,致EDLS与细胞膜钠泵结合量相对较低。非老年EH病人在较老年EH病人低的血浆EDLS浓度下,细胞膜钠泵活性已明显受抑制,不表现Ouabain抵抗现象或Ouabain抵抗程度较轻。
, 百拇医药
    EDLS可抑制肾小管细胞膜Na+泵,促进肾脏排钠,如肾小管细胞膜Na+泵对EDLS作用产生抵抗则可导致肾脏出现排钠障碍[7]。老年人EH因此可发生钠水潴留,反馈抑制体内RAS,故PRA和AngⅡ降低,本实验显示老年EH病人EDLS与PRA呈负相关。这亦说明为何老年人EH对利尿剂治疗敏感。升高的EDLS不仅抑制肾小管细胞膜钠泵,也抑制血管平滑肌细胞膜钠泵,升高外周阻力,产生高血压。Na+泵有三种亚单位,各亚单位对洋地黄糖甙(如Ouabain)敏感性明显不同[8],两组EH病人RBC-D%均降低,但在程度上以及Ouabain抵抗、EDLS和 oKos等方面有差别,可能是因Na+泵亚单位不同分子结构改变所致。

    肾近球细胞内钙离子浓度升高可抑制肾素分泌[9]。非洛地平不仅作用于血管平滑肌细胞,也作用于肾入球小动脉上由平滑肌转化来的近球细胞而影响RAS。细胞钙离子浓度下降,还通过钠钙交换等影响钠离子浓度[10],进而影响钠泵活性、EDLS产生。予钙拮抗剂非洛地平降压治疗后,老年EH病人PRA、AngⅡ、oKos明显恢复至正常或接近正常,对PRA、AngⅡ影响与Ledingham JM等报道一致[11]。EDLS无显著改变,钠泵对Ouabain抵抗减轻。进一步表明Ouabain抵抗在老年人EH中起重要作用。而老年前期和青中年EH病人PRA、AngⅡ无明显变化,与老年EH病人表现不同,这可能与两者发病机理不同或老年EH病人对钙拮抗剂更敏感有关[12]。钙拮抗剂可部分纠正这种钠代谢及体液因素异常,提示在老年EH病人中,长期予钙拮抗剂降压治疗不仅对钙代谢同时对钠代谢也是有益处的。
, 百拇医药
    This study was supported by grant from the National Natural Sciences Foundation of China (grant number 39725013)

    REFERENCES

    1 Resnick T,Laragh JH,Sealey JE,et al.Divalent cations in essential hypertension: relations between serum ionized calcium,magnesium and plasma renin activity[J] N Engl J Med 1983,309:888-891

    2 谭建聪,刘光耀,刘晓莉等.高血压病患者红细胞钠氢离子交换及钙离子内流的变化[J] 中华医学杂志 1993;73:759-760
, 百拇医药
    3 Hamlyn JM,Hamilton BP.Manunta P.Endogenous ouabain,sodium balance and blood pressure: a review and a hypothesis[J] J Hypertens 1996;14:151

    4 徐有奇,谭建聪,田玉静等.原发性高血压病人红细胞及钠泵变化[J] 放射免疫学杂志 1994;7:196-197

    5 Cumberbatch M and Morgan DB.Relations between sodium transport and sodium concentration in human erythrocytes in health and disease[J] Clin Sci 1981;60:555-564

    6 Tao QF,Soszynski DA,Hollenberg NK et al.A sensitive Na,K-ATPase assay,specific for inhibitors acting via the digitalis-binding site[J] J Cardiovasc Pharmacol 1995;25:859-863
, 百拇医药
    7 Aner BM,Imesch E,Moosmayer M.Sodium transport defect of Ouabain-resistant renal Na+,K+-ATPase[J] Bioche Biophys Res Commun 1989;165:360

    8 Tao QF,Hollenberg NK,Price DA et al.Sodium pump isoformspecificity for the digitalis-like factor isolated from human peritoneal dialysate[J] Hypertension 1996;29:815

    9 Park CS,Chang SH,Lee HS,et al.Inhibition of renin secretion by Ca2+ through activation of myosin light chain kinase[J] Am J Physiol 1996;271: c242-247
, 百拇医药
    10 谭建聪,刘光耀,刘晓莉等.高血压病患者红细胞Na+转运与Ca2+内流关系及硝苯啶干预的研究[J] 中华心血管病杂志 1995;23:391

    11 Ledingham JM,Hamada M,Simposon FO.Effect of felodipine on blood pressure,plasma renin activity and plasma aldosterone in hypertensive and normotensive rats[J] Clin Exp Pharmacol Physiol 1995;22(Suppl 1):s323-325

    12.Kalow W,Grant DM.In the metabolic and molecular bases of inherited disease[M] Pharmacogenetics 7th edi New York: McGraw-Hill,1995;293-326

    收稿日期:1999-06-15, 百拇医药